RNN - Rexahn Pharmaceuticals, Inc.
1.72 0.00 (0.00%)
After hours: 4:19PM EDT
| Previous close | 1.60 |
| Open | 1.60 |
| Bid | 1.72 x 200 |
| Ask | 1.73 x 500 |
| Day's range | 1.59 - 1.76 |
| 52-week range | 0.39 - 4.74 |
| Volume | 1,691,914 |
| Avg. volume | 250,369 |
| Market cap | 54.6M |
| Beta | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings date | 26 Feb 2018 - 2 Mar 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.83 |
- Globe Newswire•3 months ago
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, “Quinoxalinyl Piperazinamide Methods of Use”. The allowed patent application covers the use of RX-5902, also known as Supinoxin for the treatment of cancers including triple negative breast cancer either as monotherapy or in combination with other anti-tumor agents such as cytotoxic agents or immune checkpoint inhibitors.
- Associated Press•6 months ago
Rexahn reports 3Q loss
The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...
- Zacks•6 months ago
Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day.
